2019 International Congress

September 22-26, 2019. Nice, France.

View by Title View Sessions

View by Date

Monday, September 23, 2019

1:45pm-3:15pm: Opicapone improves motor and non-motor wearing off symptoms in Parkinson’s disease: an observational real-world study

C. Oehlwein, K. Mittmann, D. Sarkisjan, J. Baron, M. Oehlwein, K. Witt (Gera, Germany)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Opicapone odds ratio in relative OFF-time reduction: a post-hoc analysis from combined BIPARK-I and II data

J. Rocha, W. Poewe, O. Rascol, A. Lees, J. Ferreira, A. Santos, D. Magalhães, P. Soares-da-Silva (Coronado, Portugal)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: OPICAPONE: REAL WORLD EVIDENCE IN TOLEDO´S MOVEMENT DISORDERS UNIT

JC. Segundo-Rodríguez, N. López-Ariztegui, MI. Morales-Casado, N. García-Alvarado, A. Avila-Fernández, J. Pérez-Matos (Toledo, Spain)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Opinions and clinical practices related to diagnosing and managing patients with functional (psychogenic) movement disorders: from 2009 to 2019

K. Lafaver, D. Bega, M. Hallett, A. Lang, S. Lidstone, C. Maurer, F. Morgante, D. Perez, C. Stephen, J. Stone, T. Teodoro, A. Wu, A. Dwivedi, A. Espay (Louisville, KY, USA)

Functional (Psychogenic) Movement Disorders · Les Muses Terrace, Level 3

1:45pm-3:15pm: Opsoclonus and ataxia in the setting of synchronous primary malignancies

H. Leal Bailey, S. Wijemanne Sarathkumara, R. Knightstep (San Antonio, TX, USA)

Other · Agora 2 West, Level 2

1:45pm-3:15pm: Opsoclonus-myoclonus-ataxia syndrome associated to rubella

BED. Ines, BRA. Zeineb, HAM. Salma, ZAO. Jamel, MRI. Ridha (Tunis, Tunisia)

Ataxia · Les Muses, Level 3

1:45pm-3:15pm: Outcomes After Weighted Lumbosacral Orthosis (LSO) and Exercises in Patients with Progressive Cerebellar Ataxia

S. Mele (Philadelphia, PA, USA)

Ataxia · Les Muses, Level 3

1:45pm-3:15pm: Outcomes of the first-in-human study with a recombinant botulinum toxin E (rBoNT-E): safety and pharmacodynamic profile of rBoNT-E compared with abobotulinumtoxinA

L. Pons, C. Vilain, P. Picaut (Cambridge, MA, USA)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Pallidal surgery and physiological mechanism in choreic movements

T. Hashimoto, T. Goto, K. Yoshida, L. Johnson, J. Vitek (Minneapolis, MN, USA)

Choreas (Non-Huntington’s Disease) · Les Muses, Level 3

1:45pm-3:15pm: Paraneoplastic Cerebellar Degeneration As Initial Symptom Of Renal Cell Carcinoma

S. Souza, B. Oliveira, I. Sodré, A L. Oliveira, R. Oliveira, D. Terrana, M. Spitz (Rio de Janeiro, Brazil)

Ataxia · Les Muses, Level 3